Factors influencing warfarin dose requirements in African-Americans. - Wikidata - awgldk - TriplyDB

Factors influencing warfarin dose requirements in African-Americans.

Factors influencing warfarin dose requirements in African-Americans.

http://www.wikidata.org/entity/Q46885448

about

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans Estimation of the warfarin dose with clinical and pharmacogenetic data.A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.Warfarin dosing in patients with impaired kidney function Practical Consideration of Genotype Imputation: Sample Size, Window Size, Reference Choice, and Untyped Rate.The future of warfarin pharmacogenetics in under-represented minority groups.Pharmacogenomics of warfarin in populations of African descent.Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.Role of pharmacogenomics in the management of traditional and novel oral anticoagulants VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.Clinical applications of pharmacogenomics guided warfarin dosing.New oral anticoagulants: comparative pharmacology with vitamin K antagonists.Expanding role of pharmacogenomics in the management of cardiovascular disorders.Warfarin Pharmacogenomics in Diverse Populations.Personalized medicine: Genetic risk prediction of drug response.Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.Genetic and clinical predictors of warfarin dose requirements in African Americans.Shifting paradigms in the pharmacogenetics of warfarin.Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations.VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation.Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients

P2860

Q24641999-8D452701-DF8A-43E5-9E07-6D8ECE8E8FFB Q27002899-686843D2-914D-490E-908B-4689AD10359C Q28276514-1B8DC0C9-AFC3-4C9E-99E1-B464957C3086 Q28395337-D54F4FB1-74AB-46C7-A304-5B7DD88BE674 Q28740452-37B3DD01-3264-4956-856F-235DAC3866F2 Q33410725-3EE0EF27-51F5-4870-A172-F93B5E3FF427 Q34085379-08D75302-8EDE-42FE-95F4-E52826CA6BA7 Q34238435-83AAFB08-1BD6-4730-86E9-0E66D2EDF3E0 Q35720540-D123145B-B83F-422E-8455-CDF06FA5C6AA Q36294461-3BEEAEAA-89D1-45AE-8C75-F49693F49091 Q36629209-932C5F40-B552-4A67-AC48-2856130D594B Q36651620-A88F409F-EA57-4820-B481-72334AA6E832 Q36762797-D913D4A1-FC42-4E23-B50C-1772734F85E6 Q36835168-AFC56BFC-6522-437E-915A-2F48673FFE7C Q36848449-6CA49CB9-808E-421B-B464-656BD35EC831 Q36982736-08FB84B9-5509-4CD3-97A1-7CF112C0AA3A Q37077528-EFB5A83A-5173-4899-AB9C-B0545E73F09B Q37213180-99E70331-6BA8-4237-B149-79C75180503E Q37264555-932001DA-4479-429B-A3DC-5FF6D50946BA Q37376879-F792585C-EB7B-4E94-B477-60C6FE3B5035 Q37807280-9E3E1ED4-A993-4A10-8201-5BB1A2207751 Q38071973-70F36996-36CA-485D-8928-A8A25510561F Q38098452-5BE9E85D-328B-41E1-867F-FD92239FC860 Q38696567-71C6AEAE-25ED-481F-834F-767E372AD390 Q38756015-903EC6F9-3ED8-4634-BE34-0FFE3C64638A Q42718669-821309F8-08AA-431F-B6A8-ED0EEEB50384 Q43195085-FDA448BD-5712-4050-8FBD-C5C17C12C56B Q46316268-43CF0375-6745-4C11-AF0A-986F3AB0AE9B Q46406579-CB129A23-3EC3-4981-9CB3-2972C9C0AA04 Q46573199-EECF0DF4-3A8F-45FA-BFA3-665FA2132785 Q47345423-EF887826-A1FD-4CA2-BFE1-64062E3F5D7F Q54966850-723AD516-33AA-4F37-AA95-47FA4A4A342D Q58558658-34D654A8-C22E-48E5-A6A8-BEC03028FFA7

P2860

Factors influencing warfarin dose requirements in African-Americans.

http://www.wikidata.org/entity/Q46885448

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Factors influencing warfarin dose requirements in African-Americans.

@en

Factors influencing warfarin dose requirements in African-Americans.

@nl

type

label

Factors influencing warfarin dose requirements in African-Americans.

@en

Factors influencing warfarin dose requirements in African-Americans.

@nl

prefLabel

Factors influencing warfarin dose requirements in African-Americans.

@en

Factors influencing warfarin dose requirements in African-Americans.

@nl

P1433

Q46885448-7F36F327-0DB3-451A-AE7E-3744D541E387

P1476

Q46885448-A044D86B-8CA0-4B9D-B390-8102EC436FD5

P2093

Q46885448-42AAF5E4-33E1-4635-B20F-E402B0581455

Q46885448-6B659106-F163-4B38-8063-E1A185DF5CF3

Q46885448-7976DBCE-A424-4D77-A95F-4446887A125D

Q46885448-84B2D036-EA6A-4312-80AF-6AE5A55C5C13

Q46885448-B8A4F20E-D45D-43F7-A28F-46811203B6A3

Q46885448-F6B511BC-3EC2-423A-9FBD-4FC89657D350

P2860

Q46885448-0710BA06-9E5D-499F-B273-1BA16AF05D1C

Q46885448-100142D6-4873-4665-B763-FFCA3E8BF0AA

Q46885448-100773C7-B3B2-46ED-BC36-B97E3301B1DC

Q46885448-11A674E1-67C1-49E4-A063-90D484475B0A

Q46885448-16C26FB0-9F2E-4E4B-B5AB-1767A447E1B0

Q46885448-213CE1BF-955F-468A-B020-152BAF4B8E16

Q46885448-277A042D-BA7F-4344-96EC-2A1471964169

Q46885448-2BCD35E8-79C0-4A05-963A-AB9555D12593

Q46885448-2BEA90A3-0E4B-4864-BD3E-D4CD75B8C375

Q46885448-2ED61136-744A-4EFA-89CE-8E124C59C60C

P304

Q46885448-FAE9AD84-B6FE-4B84-8FDA-2ED97C1850C6

P31

Q46885448-536083D8-4393-4D64-AF67-DC6065142021

P356

Q46885448-B7DB044D-4ED7-4983-A5DE-0DB7F40D5914

P433

Q46885448-18CF1C85-7685-4D19-B61C-12B1EBB3C488

P478

Q46885448-E889BAF2-68BB-492D-BC15-BE126E38445C

P577

Q46885448-73C9A6FF-84E3-41D0-9A41-F5C2BAECA66D

P698

Q46885448-06CBDACE-2FAB-4CF2-8E9B-62F763566FEF

P356

14622416.8.11.1535

P1433

Pharmacogenomics

P1476

Factors influencing warfarin dose requirements in African-Americans.

@en

P2093

Cathy M Helgason

http://www.w3.org/2001/XMLSchema#string

Edith A Nutescu

http://www.w3.org/2001/XMLSchema#string

Kathryn M Momary

http://www.w3.org/2001/XMLSchema#string

Larisa H Cavallari

http://www.w3.org/2001/XMLSchema#string

Marlos Ag Viana

http://www.w3.org/2001/XMLSchema#string

Nancy L Shapiro

http://www.w3.org/2001/XMLSchema#string

P2860

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin

Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2

Association of warfarin dose with genes involved in its action and metabolism.

Evaluation of genetic factors for warfarin dose prediction

Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).

Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy.

Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K.

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group.

P304

1535-1544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14622416.8.11.1535

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18034618

http://www.w3.org/2001/XMLSchema#string